AstraZeneca PLC Form 6-K Filing Summary

This Form 6-K filing from AstraZeneca PLC details the US FDA approval of Imfinzi (durvalumab) in combination with Bacillus Calmette-Guérin (BCG) for adult patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer (NMIBC). This approval, based on the POTOMAC Phase III trial, marks the first new therapy in over 30 years for this condition. The trial demonstrated a 32% reduction in the risk of disease recurrence, progression, or death when Imfinzi was added to BCG compared to BCG alone. The filing also provides background on bladder cancer, the POTOMAC trial methodology, and details on Imfinzi's mechanism of action and its other approved indications across various cancer types. Regulatory submissions for this new indication are also under review in the EU, Japan, and other countries. The filing includes financial and company information as typically presented in a Form 6-K.